Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232

scientific article published on 25 April 2016

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232 is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2015.62.4544
P932PMC publication ID4981974
P698PubMed publication ID27114587

P50authorElizabeth A RaetzQ114529750
Michael J BorowitzQ117236346
Leonard A MattanoQ117271270
Julie Gastier-FosterQ30830859
Stephen P HungerQ64215088
Mignon L LohQ64215090
Nyla A HeeremaQ89317565
Brent L WoodQ89862846
Naomi WinickQ91287117
Wanda L SalzerQ95949129
Cheryl L. WillmanQ110811050
P2093author name stringMeenakshi Devidas
Si Chen
William L Carroll
Eric C Larsen
Catherine Cole
Alisa Eicher
Andrew A Carroll
Mark Sorenson
Maureen Haugan
P2860cites workDesign and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examplesQ24569561
Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemiaQ31960231
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.Q32061751
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.Q33645862
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaQ34314927
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaQ34707586
Biology, risk stratification, and therapy of pediatric acute leukemias: an updateQ34764504
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Q35976588
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology groupQ36058255
Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemiaQ36105259
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupQ36478435
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutQ36678136
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyQ36713493
Predicting relapse risk in childhood acute lymphoblastic leukaemiaQ38117685
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer GroupQ40748162
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemiaQ40961746
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupQ44280928
Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemiaQ44405561
Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trialQ45257171
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.Q46021126
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trialQ46543487
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemiaQ46638043
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative GroupQ47323159
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.Q50537461
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.Q52888294
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.Q52906615
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.Q52906689
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.Q52966697
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapyQ64225643
Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemiaQ69728140
Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemiaQ73666578
P433issue20
P407language of work or nameEnglishQ1860
P921main subjectlymphoblastic leukemiaQ18553852
leukemiaQ29496
dexamethasoneQ422252
methotrexateQ422232
P304page(s)2380-2388
P577publication date2016-04-25
P1433published inJournal of Clinical OncologyQ400292
P1476titleDexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232
P478volume34

Reverse relations

cites work (P2860)
Q46476461A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia
Q91565663Acute lymphoblastic leukaemia
Q39396416Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study
Q47837260Agents in Development for Childhood Acute Lymphoblastic Leukemia
Q47955491An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia
Q64066039Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models
Q92282088Cancer Treatment-Related Infertility: A Critical Review of the Evidence
Q89585955Causes of Death in Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10 Years (2008-2018)
Q92627035Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia
Q92176231Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Q59136673Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP)
Q47255380Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.
Q47706549Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
Q47199612DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Q88891952Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622
Q57462209Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Q59330178Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia
Q48272108Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Q64117250Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia
Q49711977Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
Q51738618Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
Q33774499Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia
Q46844249Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy
Q52717677Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.
Q40044204High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
Q50098629How is the Ph-like signature being incorporated into ALL therapy?
Q96693732Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Q91451448Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk
Q38769075Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Q90024651Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group
Q57284581Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization
Q53713010Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Q49497206Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study
Q92826242Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS)
Q52735368Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Q36414199Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group
Q38813392Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.
Q90226917Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics
Q39368957Novel therapy for childhood acute lymphoblastic leukemia
Q91045688PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Q49951910Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
Q40332285Potential Route of Transmission for Trichodysplasia Spinulosa Polyomavirus
Q89768692Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population
Q45985775Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Q64886346Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Q91287120Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905
Q95730173Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
Q50016386Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia
Q45105040Recent advances in the management of pediatric acute lymphoblastic leukemia
Q46103668Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing
Q64074844Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
Q47103786Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma
Q45072276Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials
Q30240217T-cell acute lymphoblastic leukemia.
Q47564553TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children
Q61445248The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
Q49088868The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients
Q48369402Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
Q91997669Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group
Q90606756Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens
Q52626221Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.
Q47258794Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
Q102058897Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07
Q92282037Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
Q30397448What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
Q57020347Will My Child Do Better if She Enrolls in a Clinical Trial?
Q91595896Zebrafish patient avatars in cancer biology and precision cancer therapy

Search more.